ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, and clinically significant drug interactions of Tranylcypromine. Safety and efficacy of tranylcypromine pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Tranylcypromine is excreted into breast milk. Avoid prescribing tranylcypromine pharmacotherapy to women who are breast-feeding. Tranylcypromine pharmacotherapy may be prescribed for patients who also require ECT. Tranylcypromine appears to produce its antidepressant action primarily by potentiating the actions of various biogenic amines by inhibiting the enzyme that catalyses their oxidative de-amination. When monoamine oxidase is inhibited by tranylcypromine, or other MAOI pharmacotherapy, tyramine absorbed from the GI tract passes freely into the general circulation. Tranylcypromine pharmacotherapy commonly has been associated with insomnia and the more serious hypertensive crisis.
